Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary A Gynecologic Oncology Group study
- 1 June 1984
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 7 (3) , 261-264
- https://doi.org/10.1097/00000421-198406000-00012
Abstract
Patients (38) with advanced or recurrent epithelial ovarian cancer no longer amenable to management with surgery, radiotherapy or chemotherapy with known activity were given piperazinedione 9 mg/m2 i.v. every 3 wk. Of the 31 patients evaluable for response, only 1 achieved a partial response (3%); there were no complete responses. Fourteen (45%) experienced progression of disease < 1 mo. after starting therapy. Adverse effects consisted primarily of myelosuppression (81%), nausea and vomiting (32%) and azotemia (29%), with 3 patients (10%) having life-threatening thrombocytopenia. While adverse effects were tolerated, the drug at the dose and schedule tested has only minimal activity at best and should not be considered for further trials in epithelial ovarian cancer.This publication has 0 references indexed in Scilit: